The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Marie McNeely
Project Title: Development of a clinical tool to predict fall risk in Alzheimer disease
Date: December 21, 2021 at 5:28 pm
Request ID: S1602
Aim 1: Identify predictors of falls in a large sample of individuals with Alzheimer disease.
Aim 2: Develop a new, simple clinical fall prediction tool that would be useful in routine care of individuals with Alzheimer disease.
Aim 3:
Aim 4:
Investigator: Susan L Stark
Project Title: Participant Retention Study
Date: December 21, 2021 at 5:28 pm
Request ID: S1603
Aim 1: Characterize the barriers and facilitators to longitudinal research in the KADRC
Aim 2: Characterize the reason for missing data in the KADRC longitudinal dataset
Aim 3:
Aim 4:
Investigator: John C. Morris
Project Title: Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer�s Disease
Date: December 21, 2021 at 5:28 pm
Request ID: S1701
Aim 1: To show that loss of blood-brain barrier (BBB) integrity links vascular injury to neuronal injury in AD
Aim 2: Examine temporal relationship between BBB permeability, cerebral blood flow (CBF) and white matter lesions
Aim 3:
Aim 4:
Investigator: Jason Hassenstab
Project Title: Pilot Study: Ambulatory Cognitive Assessments
Date: December 21, 2021 at 5:28 pm
Request ID: S1610
Aim 1: Determine the feasibility and utility of ambulatory cognitive assessments using measurment burst design.
Aim 2:
Aim 3:
Aim 4:
Investigator: Ganesh Babulal
Project Title: Racial differences in Alzheimer�s disease biomarkers and driving behavior
Date: December 21, 2021 at 5:28 pm
Request ID: S1609
Aim 1: We will determine, in a sample of 60 older adults, aged 65 years and older, with normal baseline cognition (Clinical Dementia Rating of 0), whether there are differences in values of cerebrospinal fluid (CSF) biomarkers and imaging amyloid uptake between African Americans and Caucasians
Aim 2: In the same sample, we will examine whether there are differences in African Americans and Caucasians cross-sectionally and longitudinally in daily driving behavior using an in-vehicle recording device and on a road test
Aim 3:
Aim 4:
Investigator: B, Joy Snider (WU site)
Project Title: Protocol 221AD301 A phase 3 Multicenter, RCT to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer�s Disease (ENGAGE Study)
Date: December 21, 2021 at 5:28 pm
Request ID: S1607
Aim 1: Evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the CDR-SB score as compared with placebo in subjects with early AD.
Aim 2: Evaluate the efficacy of aducanumab on MMSE, ADAS-Cog13, ADCS-ADL
Aim 3:
Aim 4:
Investigator: Beau M. Ances, MD, PhD
Project Title: Allzheimer Disease Neuroimaging Initiative 3 (ADNI3)
Date: December 21, 2021 at 5:28 pm
Request ID: S1606
Aim 1: To discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research
Aim 2: To capture rates of decline on cognitive, global and functional tests and the rate of conversion to MCI or dementia due to AD.
Aim 3: Determine the longitudinal extent and rate of amyloid and tau deposition in PET Scans and longitudinal change of cerebral tau correlated and compared with other changes in cognition and biomarkers
Aim 4: Determine which clinical, cognitive and biomarker and imaging capture detection of treatment effects and measure cognitive decline for all groups with a focus on biomarkers and Tau.
Investigator: John C. Morris, MD
Project Title: Protocol 54861911ALZ2003: Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic At Risk for Developing Alzheimer’s Dementia
Date: December 21, 2021 at 5:28 pm
Request ID: S1605
Aim 1: To deteremine whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatement, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite, in amyloid positive subjects who are asymptomatic at risk for developing Alzheimer’s dementia.
Aim 2: To assess the overall safety and tolerability of JNJ-54861911 versus placebo.
Aim 3: To assess the effect of JNJ-54861911 compared with placebo on the Clinical Dementia Rating (CDR) scale, including progression from CDR 0 to CDR 0.5 or higher
Aim 4: To assess the maintenance of JNJ-54861911 effects on markers of AB processing in CSF and plasma compared with placebo.
Investigator: Gregory Van Stavern, MD
Project Title: Ocular biomarkers in early and pre-clinical AD
Date: December 21, 2021 at 5:28 pm
Request ID: S1508
Aim 1: Assess differences in OCT metrics between normals, pre-clinical AD and early AD subjects
Aim 2: Assess changes in retinal and optic nerve blood flow in pre-clinical and early AD
Aim 3: Measure subretinal protein degradation products using OCT and compare with brain ABeta
Aim 4:
Investigator: John C. Morris, MD
Project Title: Lilly LY3202626 (BACE Inhibitor) NAVIGATE-AD Trial
Date: December 21, 2021 at 5:28 pm
Request ID: S1604
Aim 1: Safety/tolerability of LY3202626
Aim 2:
Aim 3:
Aim 4: